AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Completed · Phase 1

Conditions studied: Peptic Ulcer

In brief

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Key facts

Study ID

NCT00325715

Run by

Allergan

People needed

150

Starts

2006-04-01

Expected to finish

2006-08-01

Last updated by the study team

2011-06-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy Adult Volunteers who have provided written informed consent

You may not qualify if…

• Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease.
• Female volunteers who pregnant, nursing, or planning a pregnancy
• Volunteers with a history of drug or alcohol abuse

Where it is running

• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.